VIRAZOLE 36% WORLDWIDE SALES GAIN IN 1988 PROPELS ICN PHARMACEUTICAL GROWTH
A 36% increase in 1988 worldwide sales for Virazole (ribavirin) fueled a 37% gain in ICN Pharmaceuticals' revenues to $ 166 mil. for the year. Sales for the company's ethical dermatological products, rising 58% in the U.S., also contributed to the increase. In a Feb. 13 press release on year-end financial results, ICN attributed its sales gain to "progress across the breadth of its operations, including new product operations, acquisition of new product lines and businesses and international expansion, as well as continuing demand for existing pharmaceutical and biomedical products." ICN's overall net income rose substantially in 1988, to $ 17.8 mil., from a loss of $ 16.6 mil. in 1987. The firm attributed the improvement to a good performance by SPI, to the repurchase of the company's debt on the open market, and a to "one-time gain related to the withdrawal from a joint venture by Eastman Kodak, which was partially offset by nonrecurring expenses." The firm realized a gain of $ 13.7 mil. in 1988 from the repurchase of its long-term debt. ICN also noted that 1987 net income included an unrealized loss of $ 19.4 mil. in the company's investment portfolio. The one-time gain in the third quarter resulted from Kodak's decision to transfer its portion of the Nucleic Acid Research Institute to ICN and its subsidiaries, including Viratek. Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth